LTZ Therapeutics is an immunotherapy-focused biotech company pursuing the development of novel therapies, with the company's novel Myeloid Engager Platform, to improve clinical outcomes in patients with cancer and autoimmune diseases. With main operations in Redwood City, California and Shenzhen, China as well as a team out of Heidelberg Germany, LTZ is dedicated to developing immunotherapies capable of overcoming resistance and boosting anti-tumor immunity based on reverse translational science and emerging disease biology of tumor microenvironment.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 07/30/24 | $20,000,000 | Series A |
GL Ventures K2 Venture Partners Lapam Capital  Shunwei Capital Partners | undisclosed |
